-+ 0.00%
-+ 0.00%
-+ 0.00%

ADC Therapeutics To Present Updated Data From Phase 2 Multicenter IIT Of ZYNLONTA To Treat r/r MZL, At International Conference on Malignant Lymphoma

Benzinga·06/16/2025 11:17:07
Listen to the news

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69%

CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment

ZYNLONTA was generally well tolerated and safety was consistent with known profile

LAUSANNE, Switzerland, June 16, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA® to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented during a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20. These data will be made available online beginning on Wednesday, June 18, at 8:30 a.m. CEST. The single-arm, open-label, study is led by Izidore S. Lossos, MD, Chief, Division of Hematology Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.